Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Globus Medical, Inc. GMED continues to benefit from ... Globus is also optimistic about the recently inked deal to acquire Nevro Corporation. The acquisition of Nevro is expected to expand Globus ...

The acquisition of Nevro is expected to expand Globus Medical’s reach into the musculoskeletal market, adding an additional $2 billion market space in this niche. During the fourth quarter of ...

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Globus Medical (GMED – Research Report). The ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

According to Benzinga Pro, Globus Medical's peer group average for short interest as a percentage of float is 4.18%, which means the company has less short interest than most of its peers. Did you ...

Globus Medical, Inc. (NYSE:GMED – Free Report) – Investment analysts at Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for Globus Medical in a report released on ...